Q4 2024 Earnings Call Transcript February 4, 2025 Amgen Inc. beats earnings expectations. Reported EPS is $5.31, expectations ...

Q4 2024 . Management View. Amgen highlighted its robust performance in 2024, achieving 14 products annualizing over $1 billion in ...

My name is Julianne, and I will be your conference facilitator today for Amgen's fourth quarter and full year 2024 financial results conference call. All lines have been placed on mute to prevent ...

Less than a decade since it secured its first FDA approval for a biosimilar, Amgen’s portfolio of the copycat drugs is growing and making strong contributions to the company’s top line.

Amgen (NASDAQ:AMGN) today announced financial results for the fourth quarter and full year of 2024 versus comparable periods in 2023.

Biotechnology specialist Amgen (NASDAQ:AMGN) reported fourth-quarter and full-year 2024 earnings on Tuesday, Feb. 4, that topped analysts' consensus estimates. Analysts estimated Q4 adjusted EPS ...

All of a sudden, Amgen stock is up 15% since late December to around $299. Its rise helped push up the healthcare sector up just over 7% since hitting a bottom in late December. The better-than ...

RBC Capital analyst Gregory Renza maintained a Buy rating on Amgen (AMGN – Research Report) yesterday and set a price target of $320.00. The company’s shares closed yesterday at $289.02.

* The known adjustments are presented net of their related tax impact, which amount to approximately $1.54 per share. (a) The adjustments include noncash amortization of intangible assets and fair ...

(Reuters) - Amgen posted a higher quarterly profit on Tuesday as product sales rose 11% and said late-stage studies of key obesity drug candidate MariTide will start before mid-year but regulators ...